A new global hypertension complex ‘Amosartan’ acquired a patent in Japan
The Hanmi Pharmaceutical’s (executive director Kwan-soon Lee)new global hypertension complex ‘Amosartan’has acquired a composite patent (application number: JP2011547746) in Japan.
‘Amosartan’ is a new complexof ARB type (Losartan) and CCB type (Amlodipine) hypertension treatments with two diffe...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
